Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8722500 | 0.86 | ENPP2 (0.48) | ENPP2GSRAKR1C3PTGS2MAOB | |
| SCHEMBL7481806 | 0.84 | ENPP2 (0.47) | ENPP2GSRAKR1C3PTGS2MAOB | |
| SCHEMBL7922510 | 0.83 | KDM4E (0.47) | KDM4EDBHGAARECQL | |
| SCHEMBL10121174 | 0.82 | KDM4E (0.62) | KDM4EDBHGAARECQL | |
| SCHEMBL16473924 | 0.82 | KDM4E (0.46) | KDM4EDBHGAARECQL | |
| SCHEMBL28427675 | 0.82 | GSK3B (0.53) | ENPP2GSRAKR1C3PTGS2 | |
| SCHEMBL10136469 | 0.82 | CA2 (0.59) | KDM4EDBHGAARECQL | |
| SCHEMBL18217892 | 0.79 | GAA (0.42) | ENPP2AKR1C3KDM4EDBHGAA | |
| SCHEMBL15045392 | 0.79 | SMN1; SMN2 (0.52) | KDM4EDBHGAARECQL | |
| SCHEMBL17290620 | 0.78 | PTGS2 (0.43) | ENPP2GSRAKR1C3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053505-B | Synthesis method of important intermediate of feloxicib | 四川青木制药有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-107778204-B | Preparation method of feloxicib intermediate | 扬州天和药业有限公司 | 2020-04-03 | — | — | CN | claimed |
| CN-112624943-B | Synthesis method of feloxicib intermediate | 成都伊诺达博医药科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-112624943-A | Synthesis method of feloxicib intermediate | 成都伊诺达博医药科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-109053505-B | Synthesis method of important intermediate of feloxicib | 四川青木制药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-109053505-B | Synthesis method of important intermediate of feloxicib | 四川青木制药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| CN-107778204-B | Preparation method of feloxicib intermediate | 扬州天和药业有限公司 | 2020-04-03 | — | — | CN | disclosed |
| WO-2019062561-A1 | SYNTHESIS METHODS OF FIROCOXIB AND INTERMEDIATE THEREOF | SICHUAN QINGMU PHARMACEUTICAL CO., LTD. (CN) | 2019-04-04 | — | — | WO | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-8729114-B2 | Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20130158018-A1 | Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-6080876-A | REACTING THIOANISOLE WITH AN ACYL CHLORIDE IN THE PRESENCE OF A LEWIS ACID AND A SOLVENT, SULFONATION, EPOXIDATION, ESTERIFICATION, DECYCLIZATION AND CYCLIZATION; FORMING A POTENT CYCLOOXYGENASE-2 INHIBITORS | MERCK & CO., INC. (US) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | PREP, VIP, PEPD | ENPP2 1359/4885GSR 2495/4885AKR1C3 166/4885 |
| US-20130158018-A1 | Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S | CTSS, CTSV, CTSF | ENPP2 248/4885GSR 789/4885AKR1C3 2165/4885 |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | CD4, CCR5, MMP8 | ENPP2 2051/4885GSR 717/4885AKR1C3 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.